SAPHRIS Drug Patent Profile

Which patents cover Saphris, and when can generic versions of Saphris launch?

Saphris is a drug marketed by Abbvie and is included in one NDA. There are two patents protecting this drug and two Paragraph IV challenges.

The generic ingredient in SAPHRIS is asenapine maleate. There are twelve drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the asenapine maleate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Saphris

A generic version of SAPHRIS was approved as asenapine maleate by ALEMBIC on December 10^th, 2020.

Summary for SAPHRIS

US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	12
Patent Applications:	190
Drug Prices:	Drug price information for SAPHRIS
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for SAPHRIS
What excipients (inactive ingredients) are in SAPHRIS?	SAPHRIS excipients list
DailyMed Link:	SAPHRIS at DailyMed

See drug prices for SAPHRIS

Recent Clinical Trials for SAPHRIS

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Accutest Research Laboratories (I) Pvt. Ltd.	Phase 2/Phase 3
Amneal Pharmaceuticals, LLC	Phase 2/Phase 3
University of Cincinnati	Phase 2

See all SAPHRIS clinical trials

Pharmacology for SAPHRIS

Drug Class

Atypical Antipsychotic

Paragraph IV (Patent) Challenges for SAPHRIS

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SAPHRIS	Sublingual Tablets	asenapine maleate	2.5 mg	022117	1	2017-07-27
SAPHRIS	Sublingual Tablets	asenapine maleate	5 mg and 10 mg	022117	4	2013-08-13

US Patents and Regulatory Information for SAPHRIS

SAPHRIS is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	SAPHRIS	asenapine maleate	TABLET;SUBLINGUAL	022117-003	Mar 12, 2015	AB	RX	Yes	No					Y
Abbvie	SAPHRIS	asenapine maleate	TABLET;SUBLINGUAL	022117-001	Aug 13, 2009	AB	RX	Yes	No					Y
Abbvie	SAPHRIS	asenapine maleate	TABLET;SUBLINGUAL	022117-003	Mar 12, 2015	AB	RX	Yes	No					Y
Abbvie	SAPHRIS	asenapine maleate	TABLET;SUBLINGUAL	022117-001	Aug 13, 2009	AB	RX	Yes	No					Y
Abbvie	SAPHRIS	asenapine maleate	TABLET;SUBLINGUAL	022117-002	Aug 13, 2009	AB	RX	Yes	Yes					Y

International Patents for SAPHRIS

See the table below for patents covering SAPHRIS around the world.

Country	Patent Number	Title	Estimated Expiration
Luxembourg	91751
Finland	117923
Japan	2006342178	SUBLINGUAL OR BUCCAL PHARMACEUTICAL COMPOSITION
Hong Kong	1008417
Czech Republic	9602541

Supplementary Protection Certificates for SAPHRIS

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0746317	10C0056	France		PRODUCT NAME: ASENAPINE; REGISTRATION NO/DATE: EU/1/10/640/001 20100901
0746317	C300461	Netherlands		PRODUCT NAME: ASENAPINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET MALEAAT; REGISTRATION NO/DATE: EU/1/10/640/001-006 20100901
0746317	SZ 39/2010	Austria
0746317	SPC032/2010	Ireland		SPC032/2010: 20101210, EXPIRES: 20200228
0746317	1090035-5.L	Sweden		PRODUCT NAME: ASENAPIN; REG. NO/DATE: EU/1/10/640/001 20100901

SAPHRIS (asenapine): Market Dynamics and Financial Trajectory

Last updated: April 23, 2026

What is SAPHRIS’s market footprint?

SAPHRIS (asenapine) is an atypical antipsychotic used for schizophrenia and bipolar disorder. Its market behavior has been shaped by (1) patent and exclusivity expiry dynamics, (2) label expansions and competitive repositioning, and (3) broad class competition from lower-cost generics and entrenched branded rivals.

Key product and ownership facts

• Brand: SAPHRIS (asenapine)
• Active ingredient: asenapine
• Dosage forms: sublingual tablets (SAPHRIS) (FDA label)
• Applicant/label holder (U.S.): Schering-Plough/Merck entities historically; current commercialization structure follows post-merger corporate ownership (FDA label history)

Indications driving use

SAPHRIS’s sales trajectory tracks demand for schizophrenia and bipolar disorder populations reflected in the U.S. label. The FDA label covers:

• Schizophrenia (adults)
• Bipolar I disorder (manic or mixed episodes; with maintenance use in adults where applicable)
  (Source: FDA Prescribing Information for SAPHRIS)

How have competition and pricing pressure moved SAPHRIS’s economics?

SAPHRIS’s financial trajectory is best understood through a post-exclusivity environment typical for antipsychotics:

• Loss of brand exclusivity reduces pricing power and accelerates substitution by generics.
• Formulation-specific competition: even when generics exist for asenapine, payers can steer to lower total cost alternatives across the antipsychotic class.
• Class-level churn: branded competitors with patient support programs and strong payer contracting can displace share even when efficacy profiles are comparable for specific subpopulations.

This pattern shows up consistently across branded small-to-mid neuropsychiatric assets once multiple entry points for substitution emerge (general antipsychotic class and generics of the same molecule).

What does SAPHRIS’s revenue and profitability trajectory indicate?

Public financials do not consistently isolate SAPHRIS as a standalone line item in parent-company reporting once a product becomes a smaller component of a broader neuroscience or specialty portfolio. The result is that market-facing sales estimates and healthcare database tracking (IQVIA/Databricks-type) typically carry the closest read-through. Without those dataset-specific datapoints in the record here, the cleanest evidence-based trajectory comes from documented regulatory timelines and the post-exclusivity market shift implied by the FDA product lifecycle.

Regulatory lifecycle markers that drive revenue step-downs

• FDA approval milestone and label establishment define the initial commercial ramp.
• Subsequent exclusivity expiration and generic entry is the primary inflection for branded sales decline in antipsychotics.

SAPHRIS’s prescribing information documents the approved uses and dosing, but the financial trajectory is governed by the market transition once exclusivity ends. (Source: FDA Prescribing Information for SAPHRIS)

Where do payer dynamics concentrate impact for antipsychotics like SAPHRIS?

For schizophrenia and bipolar disorder, payer controls concentrate on:

• Formulary placement (preferred vs non-preferred antipsychotics)
• Prior authorization for non-preferred agents
• Step therapy using lower-cost alternatives
• Quantity limits and dosing conversion where applicable
• Contracting that favors manufacturers with rebates and preferred status

Once generic asenapine competes, payer contracting typically shifts the budget toward the cheapest effective option. Branded SAPHRIS pricing can still hold only if:

• patients require specific sublingual dosing behavior,
• there is a payer-approved brand access path, or
• higher-budget patient programs counterbalance generic preference.

These are structural dynamics for the class and molecule at scale. (Source: FDA label; general payer behavior reflected in market access norms for antipsychotics)

What are the most relevant demand drivers for SAPHRIS?

1. Chronic use in schizophrenia
   Long duration of therapy sustains baseline demand during the brand period; post-exclusivity, the same chronicity supports generic volume substitution.
2. Bipolar I disorder acute and maintenance treatment patterns
   Prescribing and follow-up cycles affect quarterly volatility more than annual steady state.
3. Dosing form adherence (sublingual)
   Patient and prescriber preference for route can protect share in certain payer mixes even during generic competition.

(Source: FDA Prescribing Information for SAPHRIS for dosing and approved populations)

How does SAPHRIS compare with typical branded neuropsychiatric assets?

SAPHRIS’s trajectory fits the classic branded antipsychotic shape:

• Initial adoption driven by prescriber comfort and formulary acceptance.
• Peak during exclusivity with payer contracting supporting volume.
• Decline as generic asenapine and class alternatives take share.
• Residual branded niche where payer access and patient-tolerance factors keep utilization.

This is the dominant shape across similar neuropsychiatric molecules once exclusivity ends, and the FDA label and approved uses define the ongoing addressable market even as economic capture declines. (Source: FDA Prescribing Information for SAPHRIS)

What should investors and R&D leaders watch in SAPHRIS’s market dynamics going forward?

Even without isolated line-item financials, the actionable watchlist is clear because it maps to the mechanisms that historically decide branded outcomes post-exclusivity:

1) Generic penetration rate and formulary steering

• Monitor whether payers move from “brand available” to “generic preferred” across commercial and Medicare parts.
• Track persistence of prior authorizations for SAPHRIS vs generic asenapine.

2) Contraction of specialty and psychiatrist share

• Antipsychotic switching is often driven by payer policy and prescriber adoption of lower-cost equivalents.

3) Patient support and access

• Branded assets maintain a niche when they manage exceptions and clinician workflow barriers, even if list price loses significance.

Can the FDA label be treated as a proxy for the addressable market?

Yes for clinical eligibility, not for economics. The FDA prescribing information provides the hard boundary of:

• approved indications,
• approved populations,
• dosing framework and continuity of treatment.

That boundary defines how many patients can legally be treated with SAPHRIS and therefore defines upper-end demand before payer substitution and price pressure. (Source: FDA Prescribing Information for SAPHRIS)

---

Key Takeaways

• SAPHRIS is an established atypical antipsychotic with an addressable population defined by FDA-approved schizophrenia and bipolar disorder indications.
• Market economics are dominated by exclusivity and payer substitution dynamics typical for antipsychotics: once generic competition is in place, branded pricing power compresses and share shifts toward lower total-cost options.
• The most actionable forward view is not only sales level but also payer steering, prior authorization behavior, and exception handling that can preserve a branded niche.
• The FDA label anchors the clinical market, while financial trajectory is determined by lifecycle and access mechanics.

---

FAQs

1) What is SAPHRIS’s active ingredient?

SAPHRIS’s active ingredient is asenapine.

2) What conditions is SAPHRIS indicated for?

SAPHRIS is indicated for schizophrenia and bipolar I disorder (including manic or mixed episodes and related adult uses per label). (FDA label)

3) Why does SAPHRIS’s branded revenue usually decline after exclusivity?

Because generic substitution and payer contracting shift volume toward lower-cost alternatives in antipsychotics once exclusivity ends.

4) Does the sublingual formulation affect market dynamics?

Yes. Formulation preference and adherence can preserve a limited branded niche even as pricing power declines.

5) Where can investors validate SAPHRIS sales trajectory most reliably?

Through healthcare market tracking providers (IQVIA-style) and payer claims data; the FDA label alone defines clinical scope but not economics. (FDA label)

---

References

[1] U.S. Food and Drug Administration. SAPHRIS (asenapine) prescribing information. FDA label.